Back
FDA Approves Altria's ZYN Competitor 'on! PLUS'
Back
Stock News
Themes
FDA Approves Altria's ZYN Competitor 'on! PLUS'
Asset Management
FDA Approves Altria's ZYN Competitor 'on! PLUS'
Edgen Stock
·
Jan 05 2026, 10:40
Share to
Share to
Copy link
PM
-0.32%
MO
+0.23%
source:
[1] Goldman Sees Growth Catalyst for Altria Group, Inc. (MO) After FDA Approval of on! PLUS
Recommend
Hong Kong Refinancing Jumps 26-Fold to HK$26 Billion
Jan 18 2026, 22:25
Meta's $72B Spending Plan Draws Scrutiny as BofA Sets $810 Target
Jan 18 2026, 22:03
Bloom Energy Stock Gains 72% on Data Center Demand
Jan 18 2026, 21:55
Edgen Stock·Jan 05 2026, 10:40Edgen Stock·Jan 05 2026, 10:40
Edgen Stock·Jan 05 2026, 10:40